文献速递自身炎症与 IgG4 相关病

对既往诊断为家族性地中海热的MEFV基因携带者再评估:一项秋水仙碱停药研究

Re-evaluation of MEFV carriers previously diagnosed with FMF: a colchicine discontinuation study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项回顾性队列研究评估了2024年9月至2025年3月单中心随访的136例携带杂合致病性MEFV突变的儿童患者,其中84例尝试停用秋水仙碱,72例(85.7%)成功停药,12例(14.3%)恢复治疗。随访早期无发作与成功停药相关,而关节炎预测需继续治疗;ROC分析显示治疗前6个月发作频率降低≥70.8%可强烈预测成功停药(AUC=0.883,95%CI:0.823-0.943)。作者认为部分杂合子患者可安全停用秋水仙碱,但停药后需密切监测并定期再评估。

要点

  • 84例尝试停用秋水仙碱的杂合MEFV突变患儿中,72例(85.7%)成功停药,12例(14.3%)恢复治疗。
  • 随访早期无发作与成功停药相关,而关节炎预测需继续治疗。
  • 治疗前6个月发作频率降低≥70.8%强烈预测成功停药(AUC=0.883,95%CI:0.823-0.943)。

核心结论

  • 作者认为,对于随访早期无发作的特定杂合MEFV突变个体,停用秋水仙碱是安全的,部分患者的初始家族性地中海热诊断可能需要重新考虑。
  • 作者强调停药后需密切监测这些儿童,决策应基于仔细随访和定期再评估。

研究设计与样本

  • 回顾性队列研究,纳入2024年9月至2025年3月在单一三级中心随访的携带杂合致病性MEFV突变的儿童患者。
  • 共纳入136例患者,分析成功停药与无法停药两组患者的临床特征、发作特点、炎症标志物和治疗结局。
  • 采用多因素logistic回归和ROC曲线分析识别成功停用秋水仙碱的预测因素。

主要发现

  • 136例患者中,84例尝试停用秋水仙碱,其中72例(85.7%)保持停药,12例(14.3%)恢复治疗。
  • 随访早期无发作与成功停用秋水仙碱相关,而关节炎预测需继续治疗。
  • ROC分析显示,治疗前6个月发作频率降低≥70.8%强烈预测成功停药(AUC=0.883,95%CI:0.823-0.943)。

关键数值与推荐

  • 治疗前6个月发作频率降低≥70.8%强烈预测成功停用秋水仙碱(AUC=0.883,95%CI:0.823-0.943)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: FMF is an autoinflammatory disease associated with mutations in the MEFV gene. While typically inherited in an autosomal recessive pattern, heterozygous individuals may also exhibit FMF symptoms, often with a milder disease course. The long-term management of colchicine therapy in heterozygous patients, particularly decisions regarding its discontinuation, remains a clinical challenge. METHODS: This retrospective cohort study evaluated paediatric patients with a heterozygous pathogenic MEFV mutation who were followed at a single tertiary centre between September 2024 and March 2025. Both patients in whom colchicine therapy was successfully discontinued and those in whom discontinuation was not feasible were analysed. Clinical characteristics, attack features, inflammatory markers and treatment outcomes were assessed. Multivariate logistic regression and ROC curve analyses were performed to identify predictors of successful colchicine discontinuation. RESULTS: A total of 136 patients were included. Of the 84 patients who attempted colchicine discontinuation, 72 (85.7%) remained off therapy, while 12 (14.3%) resumed treatment. Early absence of attacks during follow-up was associated with successful colchicine discontinuation, whereas arthritis predicted continued treatment. ROC analysis showed that a ≥70.8% reduction in attack frequency during the first six months of therapy strongly predicted successful discontinuation (AUC = 0.883, 95% CI: 0.823-0.943). CONCLUSION: Our findings suggest that colchicine therapy can be safely discontinued in selected heterozygous individuals who show early absence of attacks, suggesting that the initial diagnosis of FMF in some patients may warrant reconsideration. However, it is important to closely monitor these children after treatment cessation, and decisions should be guided by careful follow-up and regular reassessment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Cam V, Unal D, Sag E, et al. Re-evaluation of MEFV carriers previously diagnosed with FMF: a colchicine discontinuation study. Rheumatology (Oxford). 2025. PMID: 40512183. doi:10.1093/rheumatology/keaf340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。